Autonomix Medical

Autonomix Medical Financial Leverage

The Financial Leverage (Equity Multiplier) of Autonomix Medical (AMIX) as of Nov 22, 2026 is 1.29. In the previous year, Financial Leverage (Equity Multiplier) was 1.21 — a change of 6.48% (higher).

Financial Leverage

1.29

YoY

6.48%

Last updated:

Financial Leverage (Equity Multiplier) of Autonomix Medical is 2026 1.29 . Financial Leverage (Equity Multiplier) of Autonomix Medical was 2025 1.21 . It decreases by 6.48% higher compared to the previous year.

The Autonomix Medical Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2022
1.05 USD
Jan 1, 2023
1.34 USD
Jan 1, 2024
1.23 USD
Jan 1, 2025
1.21 USD
Jan 1, 2026
1.29 USD
The Autonomix Medical Financial Leverage history
YEARFinancial LeverageYoY
1.29+6.48%
1.21-1.82%
1.23-8.19%
1.34+28.22%
1.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autonomix Medical Stock analysis

What does Autonomix Medical do? Autonomix Medical Inc develops medical devices focused on treating peripheral nervous system diseases. The company's technology platform features a catheter-based microchip sensing array capable of detecting peripheral neural signals with up to 1,000 times sensitivity. It is developing a dual-function technology that both detects malfunctioning neural signals and ablates nerves in a single procedure for pain management. The company targets conditions like pancreatic cancer and pancreatitis, which cause severe pain requiring effective solutions. Its Autonomix catheter uses a microchip to convert body analog signals into digital signals for direct transmission to a computer. The company's products include the Autonomix catheter and its underlying technology platform. These are designed for medical professionals treating conditions involving the peripheral nervous system. The primary segments served are patients suffering from pancreatic cancer, pancreatitis, and other peripheral nervous system disorders requiring pain management solutions. The technology platform has potential applications across multiple medical fields including cardiology, renal denervation, and chronic pain management. Autonomix Medical Inc's revenue model is based on developing and commercializing its medical device technology. The company is focused on creating solutions for specific medical conditions where current treatments are inadequate. Its dual-function technology represents a novel approach to pain management by combining detection and ablation capabilities in one procedure. The company's target market includes healthcare providers seeking advanced solutions for peripheral nervous system diseases and chronic pain conditions. Autonomix Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autonomix Medical stock

Financial Leverage (Equity Multiplier) of Autonomix Medical is 1.29 in 2026.

Financial Leverage (Equity Multiplier) of Autonomix Medical changed from 1.21 to 1.29, representing a 6.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Autonomix Medical since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Autonomix Medical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Autonomix Medical

All Key Metrics — Autonomix Medical